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ABSTRACT
Burkholderia pseudomallei is the etiological agent of melioidosis, a life-threatening disease of humans and animals that occurs
primarily in Southeast Asia and northern Australia. The distribution of B. pseudomallei and occurrence of melioidosis globally
is very much evident. This soil and water-dwelling saprophyte is resilient to various environments. This organism has gained
further notoriety following the Centre for Disease Control’s classification of B. pseudomalleias a Tier 1 biological agent.
Despite several decades of clinical research, the mortality rate for melioidosis remains high. Genomics-based studies have
demonstrated the plasticity of the B. pseudomallei genome and the coding sequences consists of a myriad of functions that
enable the bacteria to adapt to these hostile environments as well as various hosts. Diagnosis is mainly based on bacterial
culture or serological assays whilst treatment is limited to third generation cephalosporins. To date, no vaccine is currently
available as an immunoprophylaxis for melioidosis. By utilising the available genome sequence, a number of virulence factors
have recently been identified and have provided more insight into the pathogenesis of B. pseudomallei. These factors include
surface associated proteins as well as secreted effector proteins and their corresponding secretion systems. In addition, a
number of recent studies on host-pathogen interaction have also demonstrated how the pathogen is able to subvert the host
immune system and survive within the cell. This review presents an overview of the current understanding on B. pseudomallei
pathogenesis and the disease melioidosis.
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INTRODUCTION
Burkholderia pseudomallei (previously known as
Pseudomonas pseudomallei) was first described as
Bacillus pseudomallei by Alfred Whitmore, a British
pathologist and C. S. Krishnaswami, an assistant
surgeon, following its isolation from a young boy
dying of pneumonia in Yangon, Myanmar in 1911
(Whitmore and Krishnaswami, 1912) . Whitmore
noted the clinical resemblance of this disease to
glanders, an abscess-forming infection caused by
Burkholderia mallei (Whitmore, 1913). The name of
this bacterium continued to evolve over the years
until 1992, when this bacterium and a number of
closely related species were incorporated into a new
genus, Burkholderia, based on the 16s ribosomal
ribonucleic acid sequences, deoxyribonucleic acid
(DNA)-DNA homology values, cellular lipid and
fatty acid composition and phenotypic
characteristics (Yabuuchi et al., 1992).
BACTERIOLOGY AND GENOMICS
General bacteriology
B. pseudomallei is a Gram negative, motile, non-
spore-forming bacillus, 0.4-0.6 μm in width and 2-
5 μm in length (Yabuuchi and Arakawa, 1993). It is
an environmental saprophytic organism which can
be isolated from water and soil in rice paddy fields
in endemic areas (White, 2003). B. pseudomallei is
a resilient organism that is capable of surviving
hostile environmental conditions, including a wide
temperature range (37 - 42ºC); some strains appear
to survive for long periods (greater than 90 days) at
5ºC under laboratory conditions (Yabuuchi et al.,
1993), acidic environments (pH 4.0 for more than
70 days) (Tong et al., 1996), prolonged nutrient
deficiency (Wuthiekanun et al., 1995) and
dehydration (soil water content of < 10% for up to
70 days) (Chen et al., 2003) but not exposure to UV
light (Tong et al., 1996).
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When isolated from blood, sputum, pus and
other body fluids, B. pseudomallei appears like
safety-pins (bipolar) under the microscope (White,
2003). In the laboratory, it grows aerobically on
most agar media and produces clearly visible
colonies within 24 hours at 37ºC. Nevertheless,
colony morphology often demonstrates
considerable variability between rough and smooth
both within and between samples (Chantratita et al.,
2007a). Ashdown’s selective medium which
contains crystal-violet, glycerol and gentamicin is
commonly used to culture the organism. The
colonies develop a characteristic appearance
(wrinkled and dry daisy-head) and they take up
crystal-violet dye from the medium (Ashdown, 1979)
(Fig. 1). More improved B. pseudomallei selective
media such as Burkholderia pseudomallei selective
agar (BPSA) (Howard and Inglis, 2003) or Francis
medium (Francis et al., 2006) have since been
developed to improve the recovery of B.
pseudomallei. The organism is oxidase positive, uses
glucose by an oxidative pathway and can be
distinguished from the closely related but less
pathogenic Burkholderia thailandensis (Ara+) by the
ability to assimilate arabinose (Smith et al., 1997).
Drug susceptibility
B. pseudomallei is resistant to a diverse group
of antimicrobials including third generation
cephalosporins whilst quinolones and amino-
glycosides have no reliable effect (Puthucheary and
Sam, 2012). Therefore, therapeutic options are
limited and the continuous presence of the organism
in patients is not fully understood. Some rare,
naturally occurring mutants are susceptible to both
aminoglycosides and macrolides because they lack
a multidrug efflux pump to export these antibiotics
(Moore et al., 1999).
The B. pseudomallei genome
The first genome sequence of B. pseudomallei
was released in 2004. The genome is relatively
large, 7.24 Mb, divided unequally between two
chromosomes (4.07 Mb and 3.17 Mb), with a G + C
content of 68% (Holden et al., 2004). At 7.2 Mb,
the genome represents one of the most complex
bacterial genomes sequenced to date. The large
chromosome encodes many of the core functions
associated with central metabolism and cell
growth,whereas the small chromosome carries more
accessory functions associated with adaptation and
survival in different niches. The B. pseudomallei
genome is estimated to carry approximately 5855
coding sequences involved in a myriad of functions,
allowing microbial survival in extreme
environments and virulence in diverse host species
including humans, gorillas, pigs and fish. A large
proportion of B. pseudomallei genes are still
unannotated or poorly characterized, raising the
need for systematic approaches to link discrete sets
of B. pseudomallei genes to their specific biological
and cellular functions. A striking feature of the
genome is the presence of genomic islands (GIs) that
together make up 6.1% of the genome. Genomic
islands contain regions of mobile genetic elements,
such as insertion sequence (IS) elements,
bacteriophages and plasmids directly acquired by
horizontal transfer from other microorganisms and
are likely to represent the major evolutionary drivers
of B. pseudomallei virulence. This also led Holden
et al. (2004) to propose that variable horizontal gene
acquisition by B. pseudomallei is an important
Fig. 1. Burkholderia pseudomallei in culture. A. Typical colony morphology of B. pseudomallei on Ashdown’s
selective medium after 72 hours incubation at 37ºC. B. Variable colony morphology that can be seen from a single
sample on Ashdown’s selective medium after 72 hours incubation at 37ºC.
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feature of recent genetic evolution and that this has
resulted in a genetically diverse pathogenic species.
A separate study using whole-genome B.
pseudomallei microarrays to examine patterns of
gene presence and absence across 94 South East
Asian strains isolated from a variety of clinical,
environmental or animal sources demonstrated that
86% of the B. pseudomallei K96243 genome was
common to all strains representing the B.
pseudomallei “core genome”, comprising genes
largely involved in essential functions (e.g. amino
acid metabolism, protein translation). In contrast,
14% of the B. pseudomallei K96243 genome,
namely the accessory genome, was variably present
across the isolates. The accessory genome comprises
of multiple genomic islands, paralogous genes and
insertions/deletions, including three distinct
lipopolysaccharide (LPS)-related gene clusters.
Noticeably, genomic islands were generally absent
in strains derived from the environment suggesting
that the B. pseudomallei accessory genome plays an
important role in microbial adaptation and virulence
in clinical isolates (Sim et al., 2008).
EPIDEMIOLOGY
The geographical distribution of B. pseudomallei
and melioidosis was comprehensively reviewed in
2005 (Cheng and Currie, 2005) and updated in 2008
(Currie et al., 2008). It is well recognized that
Southeast Asia and northern Australia are the main
endemic foci for melioidosis. In areas of Southeast
Asia where this bacterium is endemic, infection by
B. pseudomallei has been estimated to be
responsible for 20% to 30% of mortality due to
septicaemia and 40% of sepsis-related mortality.
Nevertheless, recent case reports of melioidosis have
expanded the endemic zone to southern China (Ma
et al., 2009), Taiwan (Chen et al., 2010), most of
the Indian subcontinent (Chugh, 2008) and Papua
New Guinea (Warner et al., 2008). In addition to
endemic melioidosis, there are several documented
situations where melioidosis has become established
throughout the world. Sporadic cases have occurred
in Brazil (Rolim et al., 2005), elsewhere in the
Americas (Inglis et al., 2006) and in island
communities such as New Caledonia in the Pacific
Ocean (Le Hello et al., 2005) and Mauritius in
the Indian Ocean (Issack et al., 2005) (Fig. 2). Of
note, the incidence of melioidosis has increased
incrementally over the past 20 years particularly in
the hot spots of Northern Territory of Australia
(Currie et al., 2010) and Northeast Thailand
(Limmathurotsakul et al., 2010b).
CLINICAL FEATURES
Modes of acquisition
There are several established modes of
transmission within the patient population.
Inhalation was initially thought to be the primary
mode of acquisition, based on studies on American
Fig. 2. Global map showing the categories of distribution of melioidosis and B. pseudomallei. Adapted from Currie et al.
(2008) with permission.
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soldiers in Vietnam, where it was noted that
helicopter crews seemed to have a high incidence
of the disease (Howe et al., 1971). Nevertheless,
there is no evidence to support direct human-to-
human transmission via the respiratory route. It is
now recognized that human and animal melioidosis
is thought to occur by inoculation from
contaminated soil through skin lesions, based on the
observations that people at high risk included rice
paddy farmers who spend most of the working day
wading in mud and surface water during planting
and harvesting seasons (Cheng and Currie, 2005).
The number of registered cases of infection also
increases with rainfall (Sam and Puthucheary, 2007).
Rare cases of nosocomial infections have arisen in
intensive care units (Raja et al., 2005) while vertical
transmission at childbirth and sexual transmission
have also been reported (Abbink et al., 2001).
However, zoonotic episodes are rare but highly
probable as B. pseudomallei has an extremely broad
host range (Sprague and Neubauer, 2004).
Clinical syndromes
Limmathurotsakul and Peacock (2011) have
provided an excellent overview of the clinical
presentation of melioidosis. Generally B.
pseudomallei can cause disease in apparently
healthy individuals although most infections are
asymptomatic. Once infected, the infection can
remain quiescent for long periods and become active
after months, years or decades. The longest latent
period documented to date is 62 years after exposure
in a Vietnam War veteran (Ngauy et al., 2005). The
incubation period from defined inoculating events
to onset of melioidosis was previously ascertained
as 1-21 days (Currie et al., 2000). The disease is
characterised by abscess formation (Wong et al.,
1995) where it may be localized or disseminated to
various organ systems such as lungs, skin and
subcutaneous tissues, bones and joints, liver, spleen,
pancreas, kidneys, bladder, prostate, genital organs,
brain and meninges, parotid glands, lymph nodes
and pericardium (Ip et al., 1995).
The clinical spectrum of melioidosis is
extremely diverse, consisting of four forms of
disease: acute fulminant septicaemia, subacute
illness, chronic infection and subclinical disease. In
acute form, death can occur within 24-48 hours of
the onset of symptoms (Ip et al., 1995). Subacute
melioidosis is described as prolonged febrile illness
characterized by multiorgan involvement, systemic
abscess formation and bacteraemia where clinical
manifestations can last for weeks to months or years.
Chronic melioidosis is the most common
presentation of this disease. It generally remains
undiagnosed until activated by a traumatic event or
post-mortem examination of the tissues (Brett and
Woods, 2000) whereas subclinical melioidosis is an
infection with no symptoms resulting in a chronic
carrier state. However, if decrease in immuno
competence occurs, one of the clinical forms of the
disease can occur. Recurrent disease due to
reactivation of the original infecting strain (relapse)
or different strain (re-infection) after apparent
successful treatment is well described (Maharjan et
al., 2005). Re-activation of melioidosis from a latent
focus can present as fulminant or less severe
melioidosis but it is still an important cause of
morbidity and mortality in patients who survive a
primary episode of melioidosis.
DIAGNOSIS AND MANAGEMENT
Diagnosis
Rapid diagnostics are needed for melioidosis as
the clinical presentation is nonspecific and
treatment requires specific antibiotics. Isolation of
B. pseudomallei from blood, urine, sputum, skin
lesions and throat swab samples remains the “gold
standard” of diagnosis (Limmathurotsakul et al.,
2010a). For non-sterile specimens, Ashdown’s
selective media is commonly used but,
identification of B. pseudomallei can also be made
by combining the commercial API 20NE or 20E
biochemical kit (Kiratisin et al., 2007) with a simple
screening system involving Gram stain, the oxidase
reaction, typical growth characteristic and resistance
to gentamicin and colistin (Lowe et al., 2002).
Melioidosis can also be diagnosed
presumptively using serological tests in the absence
of isolated B. pseudomallei in the specimen. A
variety of antigen detection methods have been
developed for use on direct specimens or in blood
culture supernatant. For example, direct
immunofluorescence microscopy of infected
sputum, urine and pus (Wuthiekanun et al., 2005)
or a latex agglutination test based on specific
monoclonal antibodies to LPS for definitive
identification from blood culture (Ekpo et al.,
2007). The indirect hemagglutination (IHA) test
detects antibodies against B. pseudomallei that
appear in the blood within 1-2 weeks after infection
and reach a maximal titre in 4 to 5 months
(Tiyawisutsri et al., 2005). IHA remains the most
widely used serological test for the diagnosis of
melioidosis despite its poor sensitivity and
specificity. The use of enzyme linked immuno-
sorbent assay (ELISA) to detect specific IgG and IgM
antibodies against B. pseudomallei in serum
specimens (Chantratita et al., 2007c) has improved
the diagnostic accuracy of tests based on antibody
detection.
Molecular biology techniques such as
polymerase chain reaction (PCR) and dot immuno-
assay are also used for diagnosis of melioidosis.
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Several studies demonstrated that nucleic acid-based
methods using PCR are recommended for rapid,
reliable and accurate identification of B.
pseudomallei with less biological hazard risks for
technical personnel (Gal et al., 2005; Chantratita et
al., 2007b). For instance, PCR-based techniques
previously evaluated are PCR targeting the 16S
rRNA (Ruppitsch et al., 2007) and real-time PCR
targeting type III secretion system (TTSS3) genes
(Meumann et al., 2006). Nevertheless, PCR-based
assays are not routinely used as the sensitivity is
lower on blood cultures compared to conventional
techniques, probably due to low bacterial
concentrations (Chantratita et al., 2008).
Antimicrobial therapy
Generally, disease management is based on
either an intensive intravenous phase of treatment
and/or a prolonged eradication phase of treatment.
Ceftazidime is the drug of choice for initial
intensive therapy and when the response is not
encouraging, carbapenem is administered (Cheng et
al., 2004). Following initial intensive treatment,
subsequent eradication therapy is considered
necessary for preventing recrudescence or later
relapses of melioidosis. Currently, the most effective
eradication therapy is a combination of
trimethoprim and sulfamethoxazole for 12 – 20
weeks (Limmathurotsakul et al., 2006). In the wake
of increasing reports of B. pseudomallei resistance
towards conventional antibiotic therapy, new
approaches are being taken to identify new
antimicrobials against this pathogen. Recent
preliminary reports on the isolation and
characterisation of antimicrobial peptides that
inhibit the growth of B. pseudomallei include the
LL-37 antimicrobial peptide (Kanthawong et al.,
2012), polysaccharides derived from the Acai berry
(Skyberg et al., 2012) and bovine lactoferrin
antimicrobial peptides (Puknun et al., 2013).
VIRULENCE FACTORS OF B. pseudomallei
A number of potential virulence factors have been
described and characterized in B. pseudomallei. The
factors described here have been grouped according
to the current data indicating the known role in
virulence for other pathogens or virulence in
experimental models (reviewed in Lazar Adler et al.
(2009) and Wiersinga and van der Poll (2009).
Secreted factors
Previous studies have deduced that B.
pseudomallei secretes numerous soluble factors into
the external milieu via the type II general secretory
pathway (Gsp) (DeShazer et al., 1999) and these
include several proteases, phospholipase C,
haemolysin, lecithinase, lipase and cytotoxic
exolipid that cause tissue necrosis, haemolysis,
cytolysis and death in the host (Ashdown and
Koehler, 1990). Nevertheless, whilst transposon
mutagenesis of the Gsp resulted in a failure of
secretion, the pathogen was not attenuated in an
animal model (Brett and Woods, 2000) suggesting
that these exoproducts may only play a minor role
in virulence of B. pseudomallei. Many reports have
alluded to the potential role of proteases in B.
pseudomallei pathogenicity. The serine MprA
protease has been implicated as a possible virulence
factor (Lee and Liu, 2000) causing extensive damage
to mammalian physiological proteins involved in
circumventing the detrimental effects of bacterial
secreted proteases (Chin et al., 2007).
A recent finding has discovered a highly potent
toxin named Burkholderia lethal factor 1 – BLF1,
which interferes with the protein translation
elongation factor elF4A of the host. Furthermore,
this toxin was demostrated to act as a potent
cytotoxin in eukaryotic cells and mice (Cruz-
Migoni et al., 2011). Aside from the exoproducts,
the ability to acquire iron from host sources is a
prerequisite for the successful establishment and
maintenance of most bacterial infections. Most
bacteria including B. pseudomallei have the ability
to produce and secrete iron chelator molecules,
siderophores (malleobactin) during growth under
iron-deficient conditions, to scavenge iron from
both lactoferrin and transferrin at acidic pH (Yang
et al., 1991).
Quorum sensing
Quorum sensing (QS) is a mode of bacterial
communication used by multiple bacterial species
to regulate processes such as antibiotic synthesis,
biofilm formation and virulence factor expression as
a function of population density (Miller and Bassler,
2001). In many Gram negative bacteria, quorum
sensing is mediated by acyl-homoserine-lactones
(AHLs) that are synthesized and recognized by
quorum sensing circuits composed of LuxI and
LuxR homologs for the coordination of extracellular
virulence factor expression. The B. pseudomallei
genome has been reported to have three LuxI and
five LuxR homologues. B. pseudomallei mutants of
the LuxIR quorum sensing homologues showed a
significant increase in the LD50 (lethal dose 50%)
in a Syrian hamster melioidosis model and displayed
reduced colonization in the BALB/c mouse model,
delaying time to death (Ulrich et al., 2004).
Furthermore, the extracellular secretion of B.
pseudomallei QS AHLs is highly dependent on the
B. pseudomallei BpeAB-OprB efflux pump (Chan et
al., 2007). This efflux pump is notorious for
conferring antimicrobial resistance to amino
glycosides and macrolides, optimal production of
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siderophores and phospholipase C as well as biofilm
formation. In addition, BpeAB mutants displayed
reduced levels of invasion and cytotoxicity of
human lung epithelia (A549) and human
macrophage (THP-1) cells (Chan and Chua, 2005).
Type III secretion system
The type III secretion system (TTSS) is a
syringe-like apparatus that facilitates the injection
of deleterious proteins called effectors into the
target-cell cytosol. Depending on the species, TTSS
effectors have been implicated in perturbing a
variety of host cellular processes including
cytoskeletal dynamics, gene expression, cell cycle
progression and apoptotic cell death programs
(Galan and Wolf-Watz, 2006). B. pseudomallei has
three type III secretion system (TTSS) gene clusters.
One of these clusters (the TTSS3 cluster) is very
similar to that of the human pathogens Salmonella
typhimurium and Shigella flexneri (Rainbow et al.,
2002; Stevens et al., 2002). This gene cluster
(termed bsa, Burkholderia secretion apparatus)
encodes proteins predicted to be required for the
synthesis of both the secretion apparatus and the
effector proteins. Mutants of the bsa secretion and
translocation apparatus have been shown to have
impaired intracellular survival and are unable to
escape from endocytic vacuoles, replicate or form
actin tails in the first 8 hours after infection of J774.2
macrophage cells (Stevens et al., 2002). In addition,
a separate study corroborated the findings by
showing that mutations involving the TTSS3 (as
opposed to TTSS1 and TTSS2) attenuate virulence
in a Syrian hamster model and mutants exhibited
delays in vacuolar escape, multi-nucleated giant cell
(MNGC) formation and actin-mediated intracellular
motility (Warawa and Woods, 2005). Recently, the
presence of a new secretion system, designated
T6SS, was reported. Six T6SS clusters have been
identified in the B. pseudomallei K92643 genome
(Holden et al., 2004), of which at least one was
implicated in macrophage invasion (Shalom et al.,
2007).
Surface polysaccharide and LPS
B. pseudomallei expresses several surface
polysaccharides. Capsular polysaccharides (CPS)
such as O-PS I enable bacteria to evade host defense
mechanisms by inhibiting complement activation
and phagocytic mediated killing (Reckseidler-
Zenteno et al., 2005). Inoculation with B.
pseudomallei mutants of the O-PS I biosynthesis
locus genes resulted in reduced survival in mice
(Atkins et al., 2002). In addition, another
polysaccharide, LPS (formerly O-PS II), expressed
by B. pseudomallei has been suggested to play a
role in internalization and intracellular survival of
the bacteria (Arjcharoen et al., 2007). In addition
to CPS and LPS, two other surface polysaccharides,
termed type III and IV O-PS have been identified and
shown to play important roles in virulence of B.
pseudomallei (Sarkar-Tyson et al., 2007). A number
of previous studies have confirmed that B.
pseudomallei is capable of synthesizing outer
membrane proteins (OMP) implicated in adhesion
to and invasion of host cells, resistance to
phagocytosis and the killing of host cells. These
surface associated proteins are also important in
maintaining structural integrity and in enabling
pathogens to adapt to differing environments within
the host (Harding et al., 2007).
Flagella and pili
Adhesion is a fundamental requirement for many
bacteria in order to colonize the host and cause
disease. The B. pseudomallei K96243 genome
encodes eight type IV pili-associated loci. However,
only one type IV A pilin gene, pilA, is present on
the genome. A study has shown that pilA is required
for efficient adherence of B. pseudomallei onto
cultured cells and for virulence in vivo (Essex-
Lopresti et al., 2005). The importance of flagella in
cell invasion of phagocytic and non-phagocytic
cells has been demonstrated in a number of studies
(Chua et al., 2003; Chuaygud et al., 2008).
Furthermore, in a mouse model of systemic
infection, flagella-deficient B. pseudomallei is less
virulent compared with the wild type strain
(Chuaygud et al., 2008).
INTRACELLULAR ADAPTATION OF B.
pseudomallei
Our group undertook a study on comparing
expression profiles obtained from intracellular B.
pseudomallei and the transcriptome of control
bacteria grown in cell culture medium (Chieng et
al., 2012). A majority of the bacterial genes were
down-regulated throughout the infection period (1–
6 hours) when compared to bacteria grown in vitro.
Adaptation of B. pseudomallei within macrophages
occurred rapidly with most of the changes occurring
as early as 1 hour post-infection. With time, the
number of significantly expressed genes gradually
decreased, suggesting that B. pseudomallei had
become well adapted to the intracellular
environment and displayed behaviour similar to in
vitro grown bacteria. Functional classification of
intracellularly modulated bacterial genes at any time
point showed that most of these genes encoded core
functions such as metabolism, cell envelope,
regulatory functions and transport and binding, as
well as unknown and hypothetical proteins. Only 25
genes were constantly up-regulated and were those
involved in cellular functions such as biosynthesis
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of flagella and capsule, energy metabolism and
regulatory systems. Therefore, B. pseudomallei
adapts rapidly to the intracellular environment by
relying on a strategy that includes regulation of
intracellular bacteria metabolism and growth
kinetics and the possibility of host cell immune
response avoidance through shutdown of known
virulence factors.
HOST-PATHOGEN INTERACTIONS IN B.
pseudomallei INFECTION
Host response to infectious disease can be modeled
by exposing a host to a pathogen(s) and monitoring
the molecular changes that occur over time. The
availability of host model systems for melioidosis,
such as in vitro cell-based models and in vivo
models including animals and invertebrates has
boosted pathogenesis studies.
In vitro cell-based models
In vitro studies have established that B.
pseudomallei is capable of surviving and
multiplying intracellularly within professional
phagocytes, including macrophages, monocytes and
neutrophils (Jones et al., 1996; Stevens and Galyov,
2004) or non-phagocytic cells, including respiratory
epithelial cells (Brown et al., 2002; Wongprompitak
et al., 2009) although the exact mechanism of
invasion and colonization remains unknown. When
B. pseudomallei is taken up by macrophage-like
cells, it is capable of escaping from endocytic
vacuoles into the cytoplasm, where it can replicate
by lysing the endosome membrane (Harley et al.,
1998). It also appears to be able to evade
phogosome-lysosome fusion and reside within
phagolysosomes, making use of its ability to survive
and grow in acidic environments. Moreover, B.
pseudomallei can be propelled by inducing
continuous polymerization of actin resulting in the
formation of membrane protrusions in host cells that
may project into an adjacent cell, facilitating cell-
to-cell spread of the bacteria (Kespichayawattana et
al., 2000). As a result of intracellular motility, cell
fusion leads to MNGC formation (Wong et al.,
1995).
Eventually, the ability of intracellular B.
pseudomallei to survive and replicate in
macrophages is in part due to the suppression of
macrophage killing mechanisms, including the
production of the free radical species nitric oxide
(NO). In macrophages, NO production results from
active inducible nitric oxide synthase (iNOS), an
enzyme essential for the generation of reactive
nitrogen intermediates (RNIs), which regulate
survival and multiplication of intracellular bacteria.
However, macrophages infected with B.
pseudomallei do not activate iNOS expression
(Utaisincharoen et al., 2004). A recent report has also
indicated that B. pseudomallei might evade killing
by macrophages and dendritic cells through the
induction of caspase-1-dependent host-cell death
that resembles oncosis, similar to the caspase-1-
dependent death described for Salmonella and
Shigella spp.(Sun et al., 2005).
In vivo models
While in vitro studies are of practical
importance to provide insight into the pathogenesis
of B. pseudomallei, it is critical to understand host
response to infection using in vivo models which
reflect multiple cell types, tissues and interactions,
in addition to signaling events and expression
cascades (reviewed in Warawa (2010)). Rodents are
routinely used as an in vivo model of B.
pseudomallei infection. The more susceptible
BALB/c and the relatively resistant C57BL/6 inbred
mouse strains have been used extensively in studies
of host responses to B. pseudomallei to mimic the
acute and chronic disease in humans (Hoppe et al.,
1999). Following infection with B. pseudomallei,
there is a rapid influx and activation of neutrophils.
The importance of neutrophils in innate immunity
is well recognized and further demonstrated with the
establishment of an acute B. pseudomallei infection
in C57BL/6 mice depleted of neutrophils (Easton
et al., 2007). Furthermore, myeloid differentiation
primary response gene 88 (MyD88) knockout mice
demonstrated increased susceptibility to B.
pseudomallei infection as a result of reduced
neutrophil recruitment and activation. This revealed
that MyD88, as the key signaling adaptor for most
TLRs, the IL-1-receptor and IL-18 receptor, is
involved in protective neutrophil recruitment
(Wiersinga et al., 2008). In addition, the pro-
inflammatory cytokine interferon (IFN)-α has been
shown to have an important role in early resistance
against B. pseudomallei infection with additional
vital roles played by tumor necrosis factor (TNF)-α,
(IL)-12 and IL-18 in the TH1 cell-mediated immune
response (Easton et al., 2007; Wiersinga et al.,
2007). The role of TH1 cell-mediated immune
response in protecting against melioidosis was
evident from studies demonstrating that TH1-
response-prone C57BL/6 mice are relatively
resistant to B. pseudomallei when compared with the
TH2-response-prone BALB/c mice (Hoppe et al.,
1999). However, levels of proinflammatory
cytokines were found to be significantly elevated
in patients with melioidosis, resulting in excessive
inflammation which fails to control the infection but
contributes to tissue destruction and multiple organ
failure (Gan, 2005; Wiersinga et al., 2007).
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The use of the murine model of melioidosis has
provided a detailed picture of how B. pseudomallei
affects a whole range of host mediator systems,
including toll-like receptor (TLR) signaling and
coagulation during a systemic infection. The
interaction of B. pseudomallei with TLR2, TLR4
and CD14 was confirmed by reduced tumor necrosis
factor (TNF)-α expression in leucocytes from
knockout mice. Following B. pseudomallei
infection, TLR4 knockout mice demonstrated wild-
type mortality, whereas both TLR2 and CD14
knockout mice demonstrated reduced mortality,
bacterial loads and inflammation. In addition, both
TLR4 and TLR2 have been shown to detect the LPS
of B. pseudomallei and the macrophage cytokine
response to LPS is totally dependent on binding to
TLR4 (West et al., 2008) although TLR2 has been
identified as an agonist (Wiersinga et al., 2007).
Chin et al. (2010) investigated the gene expression
profile of B. pseudomallei induced immunity by
microarray-based expression profiling of a murine
acute-phase melioidosis model and highlighted the
crucial link between innate and adaptive immunity
in responses to B. pseudomallei infection. They also
demonstrated that TLR2 was induced to initiate an
inflammatory response to the acute B. pseudomallei
infection. Nevertheless, the overwhelmed inflamma-
tory response to infection as well as tissue injury
leads to metabolic disturbances and homeostatic
imbalance which is detrimental to the host,
corroborating the notion that development of acute
disease is not due to a lack of but rather, an excess
of inflammation (Gan, 2005). More importantly, this
study has also demonstrated that suboptimal
activation and function of the downstream
complement system promotes uncontrolled spread
of the bacteria, eventually leading to death of the
infected host (summarised in Fig. 3). The strongest
risk factor associated with severe melioidosis is
diabetes. In a separate study using a diabetic mouse
Fig. 3. A summary of host immune responses to B. pseudomallei acute infection
Upon encountering B. pseudomallei, the host responds with a multitiered defense approach to protect itself. a) TLR2 and
TLR4 are responsible for initiation of host defense responses to B. pseudomallei; b) Many of the highly elevated inflammatory
genes are “alarm signals” commonly seen in general inflammation infection as represented in the shaded area; c) High
inflammation responses lead to occurrence of tissue injury, that ultimately activates the ubiquitin-mediated proteolysis; d)
Activation of the caspase and cell death programs to reduce a favorable niche for the intracellular pathogen; e) Suboptimal
activation and function of the downstream complement system promotes uncontrolled spread of intracellular pathogen. f)
Recognition of endogenous signals that resulted from tissue injury by TLRs amplifies the inflammatory responses. Arrow
represents activator connection; lines ending in bars represent inhibitory connection; solid lines represent direct activation;
dashed lines represent indirect activation. The boxes highlighted in red depict the up-regulated biological processes, while the
box highlighted in green depicts the down-regulated biological processes.
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model, Chin et al. (2011) demonstrated that the
presence of elevated glucose levels impairs the host
innate immune system by delaying the
identification and recognition of B. pseudomallei
surface structures, resulting in delayed activation of
various inflammatory and immune responses as well
as the general “alarm signal” of infection. This
could explain the increased susceptibility of
diabetic patients to this fatal disease.
A novel approach to studying the pathogenesis
of B. pseudomallei using an invertebrate model
Caenorhabditis elegans was developed by Jeddeloh
and colleagues (O’Quinn et al., 2001). They found
that nematode killing appears to be mediated by a
toxin which was shown to be UV-labile but gamma-
ray resistant. Additionally, they also showed that a
number of characterized mutations, including those
affecting the Amr multidrug efflux system, LPS O-
antigen synthesis, the general protein secretion
machinery (gspD) and flagella (fliC) had little effect
on this toxin-based killing. A separate study has also
reported the use of C. elegans to study pathogenesis
of B. pseudomallei, particularly on the perspective
of identifying pathogen virulence determinants in
B. pseudomallei by initially screening for bacterial
mutants attenuated in virulence towards C. elegans
(Gan et al., 2002). Our group has recently also
developed the B. pseudomallei – C. elegans
pathogenesis model system. We demonstrated that
direct prolonged interaction between the host (C.
elegans) and the pathogen (B. pseudomallei) is
required for a complete lethal effect as the killing
of worms requires living or proliferating bacteria
to continuously produce toxins in order to mediate
the full killing effect (Lee et al., 2007; Ooi et al.,
2012). To understand the host defense response to
B. pseudomallei infection within the context of a
whole organism, we performed a genome-wide
transcriptome analysis on infected C. elegans. The
use of a microarray-based platform technology has
successfully deciphered the C. elegans immune
response especially the signalling pathways that are
triggered and the defense arsenal that is deployed,
in response to B. pseudomallei infection.
Interestingly, the analysis revealed a previously un-
described mechanism by which B. pseudomallei
suppresses the host immune defense by specifically
targeting an intestinal transcription factor, GATA/
ELT-2, hence reducing its availability and
subsequently repressing the expression of ELT-2
transcriptional targets which are intestinally-
expressed host defense effectors. Our findings
suggest that B. pseudomallei employs a mechanism
distinct from other pathogens in causing a more
detrimental and malicious assault upon the host (Lee
et al. in preparation).
CONCLUSION
Much progress on melioidosis research has been
made in recent years, especially with respect to
genetics and genomics, epidemiology, diagnosis
and treatment, identification of virulence factors and
pathogenesis. Despite the vast advances in our
understanding of important virulence factors as well
as the molecular and cellular basis of the host
response to B. pseudomallei infection, the
pathogenic factors and specific mechanisms of
intracellular survival still remain an enigma. Thus,
continued research on identifying critical virulence
factors in B. pseudomallei is crucial to uncover a
new and effective vaccine against melioidosis.
Nonetheless, more efforts have to be devoted to
understanding the complex interaction between host
and pathogen factors that not only shed light on
pathogenic mechanisms but aid in discovering
specific protein targets for drug development to
combat this disease.
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